NSW Health reported 1,180 emergency-department presentations associated with peptide use between July 1, 2025 and September 30, 2026. The October 19 ministerial release says monthly presentations rose from five in July 2025 to more than 217 in September 2026.
The release warns about products claiming to contain substances such as BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295. Its regulatory statements concern Australia, not the United States.
Read the denominator carefully
These are presentations, not necessarily unique patients. The release does not supply a denominator of total users from which to calculate an incidence rate, and association alone cannot establish that a particular peptide caused an injury.
The primary release does not report the 833 retatrutide mentions cited in some secondary coverage, so that number is not included here as a primary-source finding.
Quality claims are not clinical assurance
NSW Health emphasizes that packaging, purity claims and influencer endorsements do not prove what a product contains or establish safety. This is a surveillance signal and a quality-control warning, not a controlled clinical comparison.
Evidence record
Event date: 2026-10-19. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.